6 research outputs found
RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus
Drug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice. Currently, there are few effective pharmacological treatments for Lewy body dementia (which includes both dementia with Lewy bodies and Parkinson’s disease dementia) apart from cholinesterase inhibitors. We reviewed several promising compounds that might potentially be disease-modifying agents for Lewy body dementia and then undertook an International Delphi consensus study to prioritise compounds. We identified ambroxol as the top ranked agent for repurposing and identified a further six agents from the classes of tyrosine kinase inhibitors, GLP-1 receptor agonists, and angiotensin receptor blockers that were rated by the majority of our expert panel as justifying a clinical trial. It would now be timely to take forward all these compounds to Phase II or III clinical trials in Lewy body dementia
Lipid Composition of Citrus Leaves from Plants Resistant and Susceptible to Citrus Bacterial Canker
Recommended from our members
RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus
AbstractDrug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice. Currently, there are few effective pharmacological treatments for Lewy body dementia (which includes both dementia with Lewy bodies and Parkinson’s disease dementia) apart from cholinesterase inhibitors. We reviewed several promising compounds that might potentially be disease-modifying agents for Lewy body dementia and then undertook an International Delphi consensus study to prioritise compounds. We identified ambroxol as the top ranked agent for repurposing and identified a further six agents from the classes of tyrosine kinase inhibitors, GLP-1 receptor agonists, and angiotensin receptor blockers that were rated by the majority of our expert panel as justifying a clinical trial. It would now be timely to take forward all these compounds to Phase II or III clinical trials in Lewy body dementia.</jats:p
Suicidal ideation in a European Huntington's disease population
BACKGROUND: Previous studies indicate increased prevalences of suicidal ideation,
suicide attempts, and completed suicide in Huntington's disease (HD) compared
with the general population. This study investigates correlates and predictors of
suicidal ideation in HD.
METHODS: The study cohort consisted of 2106 HD mutation carriers, all
participating in the REGISTRY study of the European Huntington's Disease Network.
Of the 1937 participants without suicidal ideation at baseline, 945 had one or
more follow-up measurements. Participants were assessed for suicidal ideation by
the behavioural subscale of the Unified Huntington's Disease Rating Scale
(UHDRS). Correlates of suicidal ideation were analyzed using logistic regression
analysis and predictors were analyzed using Cox regression analysis.
RESULTS: At baseline, 169 (8.0%) mutation carriers endorsed suicidal ideation.
Disease duration (odds ratio [OR]=0.96; 95% confidence interval [CI]: 0.9-1.0),
anxiety (OR=2.14; 95%CI: 1.4-3.3), aggression (OR=2.41; 95%CI: 1.5-3.8), a
previous suicide attempt (OR=3.95; 95%CI: 2.4-6.6), and a depressed mood
(OR=13.71; 95%CI: 6.7-28.0) were independently correlated to suicidal ideation at
baseline. The 4-year cumulative incidence of suicidal ideation was 9.9%.
Longitudinally, the presence of a depressed mood (hazard ratio [HR]=2.05; 95%CI:
1.1-4.0) and use of benzodiazepines (HR=2.44; 95%CI: 1.2-5.0) at baseline were
independent predictors of incident suicidal ideation, whereas a previous suicide
attempt was not predictive.
LIMITATIONS: As suicidal ideation was assessed by only one item, and participants
were a selection of all HD mutation carriers, the prevalence of suicidal ideation
was likely underestimated.
CONCLUSIONS: Suicidal ideation in HD frequently occurs. Assessment of suicidal
ideation is a priority in mutation carriers with a depressed mood and in those
using benzodiazepines
Suicidal ideation in a European Huntington's disease population
Previous studies indicate increased prevalences of suicidal ideation,
suicide attempts, and completed suicide in Huntington's disease (HD) compared
with the general population. This study investigates correlates and predictors of
suicidal ideation in HD.
METHODS: The study cohort consisted of 2106 HD mutation carriers, all
participating in the REGISTRY study of the European Huntington's Disease Network.
Of the 1937 participants without suicidal ideation at baseline, 945 had one or
more follow-up measurements. Participants were assessed for suicidal ideation by
the behavioural subscale of the Unified Huntington's Disease Rating Scale
(UHDRS). Correlates of suicidal ideation were analyzed using logistic regression
analysis and predictors were analyzed using Cox regression analysis.
RESULTS: At baseline, 169 (8.0%) mutation carriers endorsed suicidal ideation.
Disease duration (odds ratio [OR]=0.96; 95% confidence interval [CI]: 0.9-1.0),
anxiety (OR=2.14; 95%CI: 1.4-3.3), aggression (OR=2.41; 95%CI: 1.5-3.8), a
previous suicide attempt (OR=3.95; 95%CI: 2.4-6.6), and a depressed mood
(OR=13.71; 95%CI: 6.7-28.0) were independently correlated to suicidal ideation at
baseline. The 4-year cumulative incidence of suicidal ideation was 9.9%.
Longitudinally, the presence of a depressed mood (hazard ratio [HR]=2.05; 95%CI:
1.1-4.0) and use of benzodiazepines (HR=2.44; 95%CI: 1.2-5.0) at baseline were
independent predictors of incident suicidal ideation, whereas a previous suicide
attempt was not predictive.
LIMITATIONS: As suicidal ideation was assessed by only one item, and participants
were a selection of all HD mutation carriers, the prevalence of suicidal ideation
was likely underestimated.
CONCLUSIONS: Suicidal ideation in HD frequently occurs. Assessment of suicidal
ideation is a priority in mutation carriers with a depressed mood and in those
using benzodiazepines